Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk
Human Psychopharmacology: Clinical and Experimental · 2025
DOI: 10.1002/hup.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2025. Verfasst von Maurizio Pompili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'Andrea Hospital, Sapienza University of Rome, Rome, It…. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Suicidal Ideation, Antidepressive Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Objective
Treatment‐resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real‐world outpatient setting. A secondary objective was to explore the potential benefits of intranasal esketamine on hopelessness and suicide risk (suicidal ideation and suicide attempts).
Methods
Twenty‐one patients diagnosed with treatment‐resistant depression were treated with intranasal esketamine. Depressive symptoms (MADRS and BDI), suicide risk (C‐SSRS), and hopelessness (BHS) were assessed. We conducted a mixed model for repeated measures analysis to evaluate changes from baseline (T0), 3‐month follow‐up (T1), and 6‐month follow‐up (T2).
Results
Results indicated that depressive symptoms decreased over time. Specifically, both clinician and self‐report measures show lower levels of depressive symptoms at 3‐month and 6‐month follow‐up. We also found a significant decrease in the presence of suicidal ideation between T0 and T2. Finally, patients also reported a reduction in hopelessness levels over time.
Conclusions
Our findings indicate an overall response regarding depressive symptoms, hopelessness, and suicidal ideation after esketamine in treatment‐resistant depression at 3‐month and 6‐month follow‐up assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
- Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
- Psychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Psychiatry Unit, Sant'Andrea Hospital, Rome, Italy.
ORCID-Profile: Maurizio Pompili
Zitieren
APA
Pompili, M., Trocchia, M. A., Longhini, L., Dispenza, E., Di Legge, C., Sarubbi, S., Erbuto, D., & Berardelli, I. (2025). Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.70008
Vancouver
Pompili M, Trocchia MA, Longhini L, Dispenza E, Di Legge C, Sarubbi S, et al. Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk. Human Psychopharmacology: Clinical and Experimental. 2025. doi:10.1002/hup.70008
BibTeX
@article{Pompili2025,
author = {Pompili, Maurizio and Trocchia, Maria Anna and Longhini, Ludovica and Dispenza, Eva and Di Legge, Cristina and Sarubbi, Salvatore and Erbuto, Denise and Berardelli, Isabella},
title = {Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2025},
doi = {10.1002/hup.70008}
}
EUVIMED